Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - Complications and organ damages

Complications and organ damages

Ahmad Awada, Chef de Service, Medical Oncology - Karen Willard-Gallo, Laboratory Head, Molecular Immunology - Aspasia Georgala, Infectious Disease Physician - Maher Khalife, Chef de Service, Anesthesiology- Alain Roman, Chef de Service, Intensive Care

ULB, Bordet Institute and CHU Saint-Pierre
" The limited capacity of intensive care unit (ICU) beds and the high mortality of patients requiring ICU care after COVID-19 infection are major problems that urgently require solutions. Early evidence suggests that an individual patient's immune responses to this virus are a key factor in their disease pathogenesis. This response can be further compounded by underlying factors, which for patients at Bordet can be exacerbated by their cancer status. A recent study shows that some cancer patients (particularly lung, blood or metastatic cancer patients) are three times more likely to die from COVID-19 infection. Thus, there is an important need to understand and identify immune biomarker(s) that measure functionality of innate and/or adaptive immunity in the blood with rapid turnaround to provide much needed information for clinical decision making. The anticipated results of this collaborative research project include the identification of...

Caroline Huart, MD, PhD - Bernard Hanseeuw, MD, PhD - Valérie Hox, MD, PhD - Pascal Kienlen-Campard, PhD- Vincent Van Pesch, MD, PhD

UCLouvain and Cliniques universitaires Saint-Luc - FNRS
" Anosmia has been reported to be a major symptom of COVID-19. Since high viral loads are found in the nasal cavity of patients and since single-cell analyses found that olfactory sustentacular and stem cells highly express ACE2 and TMPRSS2, it is suspected that cells of the olfactory neuroepithelium are a preferred target of the virus. Some COVID-19 patients present with neurological symptoms. Interestingly, it has been reported that the former SARS-CoV, can ascend intracranially, possibly via the olfactory nerves. Since olfactory receptor neurons form a direct connection between the nasal cavity and the brain, we hypothesize that these cells act as a gateway towards the brain in some patients. The main aims of the projects are (1) to investigate the pathophysiology of COVID-related olfactory dysfunction and (2) to investigate whether olfactory receptor neurons could be the entry site of SARS-CoV2 to the brain. "
Funding...

Cécile OURY, FNRS Research Director

GIGA - ULiège - FNRS
" Covid-19 is associated with a high risk of thrombotic disease, both in the venous and arterial circulations. As President of the Belgian Society on Thrombosis and Hemostasis (BSTH), I am coordinating the creation of national algorithms for thromboprophylaxis and anticoagulation of Covid-19 patients by a group of experts. These algorithms will be included in the Sciensano Covid-19 guidelines. "
Publication References: In preparation
Contact: Cécile Oury, PhD President of the Belgian Society on Thrombosis and Haemostasis Research Director F.R.S.-FNRS Head of the Laboratory of Cardiology GIGA-Cardiovascular Sciences University of Liège (B34) 1 Avenue de l'Hôpital 4000 Liège (Sart-Tilman) Belgium Tel: +32 (0)4 366 24 87 This email address is being protected from spambots. You need JavaScript enabled to view it.

Charles Pilette, Professor

UCLouvain, St-Luc
" We aim to characterize the reprogramming of structural cells of the lungs that are direct targets of the SARS-CoV-2, namely type 2 alveolar epithelial cells and endothelial cells, as well as their potential role in the induction of the (hyper)inflammatory phase of the disease leading to acute lung injury. The skills of our laboratory in lung and mucosal immunology research that are relevant to this field are (1) access to precious human lung tissue (e.g. from SARS-CoV-2 patients), (2) multiplex immunofluorescence staining and isolation of structural cells (e.g. alveolar epithelial cells, endothelial cells) from the human lung, as well as (3) their characterization using cell culture-based readouts and (in collab. with the UCL-CTMA) genetic sequencing. "
Funding: FNRS CUR, application submitted on 01-05-20.
Publication References: 1. Gohy ST, Hupin C, Fregimilicka C, Detry BR, Bouzin C, Gaide Chevronay H, Lecocq M, Weynand B, Ladjemi MZ, Pierreux CE, Birembaut P...

Didier Serteyn, Professor - Justine Ceusters, CSO RevaTis - Charlotte Sandersen, Professor

ULiège and RevaTis SA (Spin Off)
" The project aims to assess the effects of muscle derived stem cells on a preclinical model of acute respiratory distress syndrome induced by a perfusion of endotoxins. We focused on the modulation of neutrophil excessive activation. RevaTis developped a GMP production of muscle derived Mesenchymal Stem Cells and is authorized to produce clinical batches. The IPCLab (Liege University) developed an ARDS model in pigs. We aim to demonstrate a reduction of the ARDS severity, a reduction of the cytokines storm and a modulation of the excessive activation of neutrophils observed in ARDS. "
Funding: Research grants from Ulg (POC) and FNRS (CURE) are pending. RevaTis supplies muscle derived Stem Cells for R&D projects
Publication References: Sci Rep. 2017 Apr 6;7(1):696. doi: 10.1038/s41598-017-00803-7. From skeletal muscle to stem cells: an innovative and minimally-invasive process for multiple species. Ceusters J, Lejeune JP, Sandersen C, Niesten A...

Etienne CAVALIER, Professor

ULiège, CHU de Liège, CIRM
" This study aims at measuring the activity of the Angiotensin-2 enzyme (AT2) by LCMS./MS in COVID patients. This enzyme plays a key-role in the mechanisms of the infection by the SARS-COV2 "
Funding: Fondation Leon Fredericq
Contact: Professor Etienne Cavalier Department of Clinical Chemsitry University of Liège, CHU de Liège This email address is being protected from spambots. You need JavaScript enabled to view it.

Jean-Paul Deslypere, MD

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931

Joëlle Nortier, Dr

ULB, Faculty of Medicine, and Erasme Hospital
Suivi longitudinal de biomarqueurs sériques et urinaires de l'atteinte rénale aiguë associée au COVID-19 : impacts diagnostique et pronostique. " L'objectif principal de cette étude est de caractériser l'atteinte rénale aiguë par le virus SARS-COV2 chez des patients hospitalisés présentant une maladie COVID-19 à l'aide de biomarqueurs sériques et urinaires précoces et spécifiques à certains segments du néphron. L'objectif secondaire est d'établir une corrélation entre l'évolution de ces marqueurs observée durant la phase aiguë de l'insuffisance rénale et le passage éventuel à un stade chronique. "
Funding: Crédit Urgent de Recherche (CUR) sollicité auprès du FNRS
Publication References: BUNEL V, SOUARD F, ANTOINE M-H, STEVIGNY C, NORTIER JL. Nephrotoxicity of Natural Products: Aristolochic Acid and Fungal Toxins. In McQueen C.A., Comprehensive Toxicology, Third Edition. Vol 14, Oxford Elsevier Ltd (2018), pp 340-379. BUNEL V, TOURNAY Y...

Jurga Marcin, PhD

EXO Biologics
" EXO Biologics plans to extend its research and development program towards the COVID-19 crisis by using its unique and disruptive technology based on Extracellular Vesicles. These nanometer size particles are gaining momentum in the scientific community as potential alternatives to stem cell and biologic drugs therapies in the fields of immunology, neurology, oncology, cardiology, gastroenterology among others. EXO Biologics has 12 years of experience in cell-based regenerative medicine and 8 years of experience in Extracellular Vesicles. Our advancements in research will play an important role for our company mission to provide affordable and accessible therapies to patients with unmet medical needs. "
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Maya Hites, Associate Professor

CUB-Erasme
" "Background: There are no currently approved therapeutics for COVID-19 disease. This disease causes significant morbidity and mortality. Main Objectives: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19 patients. The primary endpoint is subject clinical status (on a 7-point ordinal scale) on Day 15. The secondary objectives are to evaluate clinical, and virological efficacy, and safety of different investigational therapeutics as compared to the control arm. Study design: This is a prospective, worldwide, adaptive, randomized, controlled, open study comparing 4 different treatments for COVID-19. The protocol is based on the WHO Master protocol of the Solidarity trial. The DisCoVeRy protocol previews more data collection and lower dosage regimens of Hydroxychloroquine than in the SOLIDARITY trial. Randomization is performed by...

Mona Momeni, MD, PhD

UCLouvain/Cliniques universitaires Saint-Luc 
" COVID-19 pandemic has an important impact on the health care provided by the anesthesiologists. Different societies of anesthesiology have provided guidelines and recommendations on how to manage patients who have been tested positive for COVID-19 or suspected to be infected. It is therefore important to know whether these guidelines have been implemented or were possible to be implemented. Otherwise patients who are presenting COVID-19 often show pulmonary complications. The airway management and the ventilation management of these patients can be therefore challenging and can possibly influence their outcome. It is thus important to obtain a large database with information about the characteristics of these patients, how these patients have been managed and their in-hospital outcome. Information regarding the correct implementation of guidelines is as well necessary for future guidance of health care providers. "
Funding: None
Contact...

Olivier Debeir, Professor - Olivier Van Hove, Kinesiologist

ULB/ERASME
" Severe COVID-19 patients have a greater risk of long-term health issues and sometimes develop permanent lung damage or fibrosis needing a long treatment to enhance their quality of life. The project aims to better quantify the breathing parameters of a patient to assess his revalidation evolution. A 3D image acquisition based system, provides contacless and non invasive measure. The system can be used as a complementary diagnosis tools as well for a quantitative follow up. "
Funding: So far the project is supported by volunteering inside the ULB/Laboratory of Image Synthesis and Analysis (LISA) and the Erasme Hospital
Contact: Olivier Debeir < This email address is being protected from spambots. You need JavaScript enabled to view it.> & Olivier Van Hove < This email address is being protected from spambots. You need JavaScript enabled to view it.>

Olivier DURANTEAU, Doctor

Erasme Hospital
" Precise the frequency of thrombosis events in COVID19 patients "
Funding: No need
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Serge Goldman, Scientific Director

CMMI
" The Center of Microscopy and Molecular Imaging (CMMI) is currently involved in establishing an accurate SARS-CoV-2 virus distribution topography in the organs and various cells of patients who died in COVID-19 units by providing immunohistochemistry and electron microscopy services (study director Pr. Isabelle Salmon). We have also developed and are currently offering preclinical multimodal quantitative imaging - of lung inflammation - of bacterial population (pathogen or no pathogen) - and of viral infection by isotopic imaging. All these models enable the understanding of pulmonary pathological features caused by SARS-viruses such as CoVID-19. From molecular to humanized animal models, the CMMI provides customized imaging solutions to research projects on Coronavirus The CMMI is also a proud partner of the ULB diagnostic platform set-up in Gosselies to face the epidemic of SARS-CoV2. "
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Comment: The CMMI was co-founded by ULB et UMons and is supported...

Sofia Morra, FNRS Research Fellow

ULB, Hôpital Erasme - FNRS
Lung injury, endothelial dysfunction and the role of RAAS during SARS-CoV-2 invection. " The first case of a person infected with SARS-Cov-2 virus can be tracked back on November the 17th, 2019, in China. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 outbreak a pandemic. On April 13, COVID-19 is affecting 210 countries and territories worldwide, about 2 million positive cases have been officially declared along with 115.000 deaths. The real number of infected and deaths is scarily higher, considering that up to 65% people are asymptomatic and thus, not tested. The percentage of patients with COVID-19 needed for intensive care unit (ICU) varied from 5 to 32% in Wuhan, China. It was up to 9% in Lombardy, Italy. According to available data from Lombardy, 99% of patients admitted to the ICU needed respiratory support (88% invasive ventilation, 11% non invasive ventilation). In this unprecedented time, while SARS-Cov-2 virus is halting...

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11

info@COVID19-WB.be

Brussels & Wallonia against COVID19